Original StudyPrimary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer
Introduction
Various clinical and pathologic markers and interventions are known to affect the outcomes of patients with metastatic colorectal cancer. Among them, the patient’s age, performance status, and extent of the metastatic disease (for example, number of metastases sites) have been identified as important prognostic markers that correlate with survival.1, 2 Furthermore, molecular profiles of the tumors such as the presence of the BRAF mutation (noted in about 5% to 11% of metastatic colorectal cancer) are associated with differential outcomes.3 Various interventions such as chemotherapy, biological agents, metastasectomy, and possibly primary tumor resection have contributed to prolonging the longevity of patients with metastatic colorectal cancer.1 Emerging data suggests that that the primary tumor location may impact the outcomes of patients with metastatic colorectal cancer.4, 5, 6, 7, 8 Several reports have shown that patients with tumors originating in the right side of the colon tend to have inferior survival.5, 6, 7, 8 For example, a retrospective analysis of a large randomized trial that evaluated cetuximab or bevacizumab as a first-line therapy in combination with chemotherapy, for patients with metastatic colorectal cancer, revealed that patients with KRAS wild-type right-sided primary tumors had a median overall survival (OS) of 19.4 months compared with an OS of 34.3 months of patients with left-sided tumors (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.32-1.84).5, 9 Likewise, retrospective analyses of CRYSTAL (Cetuximab Combined with Irinotecan in First-line Therapy for Metastatic Colorectal Cancer) and FIRE-3 (FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab for metastatic colorectal cancer) trials that examined first-line cetuximab-based combination therapy showed that patients with right-sided tumors had inferior survival compared with the patients with left-sided metastatic disease.6
It is important to know that most emerging information about the prognostic significance of the location of the primary tumor came from retrospective analyses of first-line clinical trials in patients with metastatic colorectal cancer. There is limited information available about the prognostic significance of the primary tumor location in real-world patients. We conducted this large population-based cohort study using individual patient data to confirm the prognostic importance of the primary tumor location in the general population with metastatic colorectal cancer.
Section snippets
Study Population
The University of Saskatchewan’s Research Ethics Board approved the study. Patients with newly diagnosed synchronous metastatic adenocarcinoma of the colon and rectum, from January 1992 to December 2010, living in the province of Saskatchewan, Canada, comprised the study cohort. Patients with neuroendocrine tumors, melanoma, lymphoma, gastrointestinal stromal tumors, and other histologic malignant diagnoses of colon and rectum were excluded. Ascending and transverse colonic tumors (up to the
Demographic Information
A total of 1947 eligible patients were identified (Figure 1). Thirty-nine percent of patients had right-sided tumors, and 61% had left-sided tumors (Table 1). The median age was 70 years (interquartile range, 60-78 years), and the male to female ratio was 1.3:1. Twenty-nine percent of patients had WHO performance status of > 1, 37% had stage IVb disease, and 47% received chemotherapy. Fifty percent of women, compared with 38% of men, were diagnosed with a right-sided primary tumor (P < .001).
Discussion
In agreement with the previous published observations, our study showed that patients with right-sided primary tumors had inferior survival compared with patients having left-sided primary tumors. The correlation between survival and location of the primary tumor was maintained after adjusting for important prognostic factors in a multivariate analysis. Patients with right-sided tumors had a 40% increased risk of mortality compared with patients whose tumor originated in the left colon and
Disclosure
The authors have stated that they have no conflicts of interest.
Acknowledgment
The study was supported by a research grant from Saskatchewan Cancer Agency. The authors would like to thank Dr Haider, Dr Zaidi, Mr Riaz Alvi, Mrs Carla Woites, Dr Tong Zhu, and the Saskatchewan Cancer Agency for their support for this project.
References (14)
- et al.
The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials
Eur J Cancer
(2017) - et al.
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer
Ann Oncol
(2013) - et al.
Advances in the management of colorectal cancer: from biology to treatment
Int J Colorectal Dis
(2014) - et al.
Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect
Ann Surg Oncol
(2005) - et al.
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Br J Cancer
(2011) - et al.
Impact of primary tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance)
J Clin Oncol
(2016) - et al.
Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials
JAMA Oncol
(2017)
Cited by (19)
Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy
2021, Journal of Thoracic and Cardiovascular SurgeryCitation Excerpt :Our findings, in addition to those from previous investigators, have also raised the important issue of the differential risk of pulmonary occurrence. Although we acknowledge that our cohort was defined by the existence of pulmonary metastatic disease, previous studies have established that right-sided colorectal cancer cases have an increased propensity for the development of extrahepatic metastases, most commonly lung, and that left-sided tumors are most likely to spread to the liver.6 Although yet absent from consensus screening recommendations, separate screening processes for lung metastases according to colorectal cancer tumor location could be seen in future management of this disease.
Prognostic value of primary tumor location in colorectal cancer: an updated meta-analysis
2023, Clinical and Experimental Medicine